ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ALN-ANG3

Its studies are mostly in Diabetic Nephropathies · Hyperlipidemias, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Nov 21, 20252 company-led studies, 2 open or runningNext primary completion: Dec 4, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals22 open or runningphase 2since Nov 21, 2025Jun 5, 2024Dec 4, 2026phase 1 · NCT06452771

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 5, 2024First study: phase 1 study in Healthy Volunteers With HyperlipidemiaFirst studyNCT06452771 · 59 enrolled · New Zealand
  2. Nov 21, 2025Phase 2 study in Diabetic NephropathiesPhase 2 reachedNCT07271186 · 195 planned · United States

Ahead

  1. Dec 4, 2026Primary completion: phase 1 study in Healthy Volunteers With HyperlipidemiaNCT06452771
  2. Oct 13, 2028Primary completion: phase 2 study in Diabetic NephropathiesNCT07271186

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07271186Diabetic Nephropathies · United States2RecruitingOct 13, 2028195
NCT06452771Healthy Volunteers With Hyperlipidemia · New Zealand1Active, not recruitingDec 4, 202659

How it is read

Names in the registry

  • “ALN-ANG3”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.